Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum

Clinical Biochemistry

Volumn 45, Issue 12, 2012, Pages 920-927

  Koivula, Marja Kaisa ^a   Risteli, Leila ^a   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Bone formation; Bone metastasis; Immunoassay; Osteoporosis; Paget's disease

Indexed keywords

BIOLOGICAL MARKER; PROPEPTIDE OF TYPE I PROCOLLAGEN PROTEIN; UNCLASSIFIED DRUG;

ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTURE; HUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, GEL; COLLAGEN TYPE I; HUMANS; IMMUNOASSAY; MOLECULAR WEIGHT; OSTEITIS DEFORMANS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 84863875522     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.023     Document Type: Review

References (72)

1. Stein G.S., Lian J.B., Owen T.A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 1990, 4:3111-3123.
2. Risteli J., Winter W.E., Kleerekoper M., Risteli L. Bone and mineral metabolism. Tietz textbook of clinical chemistry and molecular diagnostics 2012, 1733-1801. Elsevier, St. Louis, MO, USA. 5th Edition. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds.).
3. Risteli J., Risteli L. Products of bone collagen metabolism. Dynamics of bone and cartilage metabolism: principles and clinical applications 2006, 391-405. Chapter 23, Academic Press, San Diego, CA, USA. 2nd edn. M.J. Seibel, S.P. Robins, R.J.P. Bilizikian (Eds.).
4. Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996, 42:947-954.
5. Makareeva E., Han S., Vera J.C., Sackett D.L., Holmbeck K., Phillips C.L., et al. Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res 2010, 70:4366-4374.
6. Bailey A.J., Sims T.J., Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type I homotrimer. Int J Biochem Cell Biol 2002, 34:176-182.
7. Kauppila S., Jukkola A., Melkko J., Risteli L., Turpeeniemi-Hujanen T., Vuorinen K., et al. Aminoterminal propeptide of the alpha1-homotrimer variant of human type I procollagen (hotPINP) in malignant pleural effusion. Anticancer Res 2001, 21:2293-2296.
8. Jensen L.T., Olesen H.P., Risteli J., Lorenzen I. External thoratic duct-venous shunt in conscious pigs for long-term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990, 40:620-624.
9. Ihlberg L., Haukipuro K., Risteli L., Oikarinen A., Kairaluoma M.I., Risteli J. Collagen synthesis in intact skin is suppressed during wound healing. Ann Surg 1993, 4:397-403.
10. Melkko J., Hellevik T., Risteli L., Risteli J., Smedsrød B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994, 179:405-412.
11. Schytte S., Hansen M., Møller S., Junker P., Henriksen J.H., Hillingsø J., et al. Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest 1999, 59:627-634.
12. Qvist P., Petersen K.R., Jespersen J., Vinberg N., Christiansen C. Lack of hepatic metabolism of C-telopeptides of type I collagen. Clin Chim Acta 2006, 366:344-347.
13. Crofton P.M., Evans N., Taylor M.R.H., Holland C.V. Procollagen type I amino-terminal propeptide: pediatric reference data and relationship with procollagen type I carboxyl-terminal propeptide. Clin Chem 2004, 50:2173-2176.
14. Koivula M.K., Richardson J., Leino A., Valleala H., Griffiths K., Barnes A., et al. Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin Biochem 2010, 43:1453-1457.
15. Rasmussen B.H., Teisner B., Bangsgaard-Petersen F., Yde-Andersen E., Kassem M. Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum, and serum from patients with chronic renal failure. Nephrol Dial Transplant 1992, 7:902-907.
16. Jensen P.B., Rasmussen H.B., Pedersen F.B. Serum concentration of the aminopropeptide of type I procollagen in patients on haemo- and peritoneal dialysis. APMIS 1997, 105:371-377.
17. Koivula M.K., Ruotsalainen V., Björkman M., Nurmenniemi S., Ikäheimo R., Savolainen K., et al. Difference between total and intact assays for N-terminal propeptide of type I procollagen (PINP) reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem 2010, 47:67-71.
18. Marin L., Koivula M.K., Jukkola-Vuorinen A., Leino A., Risteli J. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 2011, 48:447-451.
19. Brandt J., Krogh T.N., Jensen C.H., Frederiksen J.K., Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 1999, 45:47-53.
20. Fay T.N., Jacobs I., Teisner B., Poulsen O., Chapman M.G., Stabile I., et al. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. Eur J Obstet Gynecol Reprod Biol 1988, 29:73-85.
21. Risteli J., Niemi S., Trivedi P., Mäentausta O., Mowat A.P., Risteli L. Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clin Chem 1988, 34:715-718.
22. Risteli J., Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995, 22(Suppl. 2):77-81.
23. Ueda M., Inaba M., Okuno S., Nagasue K., Kitatani K., Ishimura E., et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002, 40:802-809.
24. Alvarez L., Torregrosa J.V., Peris P., Monegal A., Bedini J.L., Martinez De Osaba M.J., et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J Bone Miner Metab 2004, 22:254-259.
25. Kit insert Total P1NP Elecsys and Cobas® analyzers, Roche Diagnostics, Mannheim, Germany 2006-11, 2/4. (V 4 English).
26. Tähtelä R., Turpeinen M., Sorva R., Karonen S.L. The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin Biochem 1997, 30:35-40.
27. Kit insert IDS-iSYS Intact PINP 2009-12, 1-4. 22, Immunodiagnostic Systems Ltd, Boldon, England, (English).
28. Ørum O., Hansen M., Jensen C.H., Sørensen H.A., Jensen L.B., Hørslev-Petersen K., et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
29. Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.
30. Suvanto-Luukkonen E., Risteli L., Sundström H., Penttinen J., Kauppila A., Risteli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 1997, 266:105-116.
31. Niemelä O., Risteli L., Sotaniemi E.A., Risteli J. Heterogeneity of the antigens related to the aminoterminal propeptide of type III procollagen in human serum. Clin Chim Acta 1982, 124:34-44.
32. Luchavova M., Zikan V., Michalska D., Raska I., Kubena A.A., Stepan J.J. The effect of timing of teriparatide treatment on the circadian rhythm on bone turnover in postmenopausal osteoporosis. Eur J Endocrinol 2011, 164:643-648.
33. Blumsohn A., Naylor K.E., Timm W., Eagleton A.C., Hannon R.A., Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res 2003, 18:1274-1281.
34. Brown J.P., Albert C., Nassar B.A., Adachi J.D., Cole D., Davison K.S., et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009, 42:929-942.
35. Yang L., Grey V. Pediatric reference intervals for bone markers. Clin Biochem 2006, 39:561-568.
36. Huang Y., Eapen E., Steele S., Grey V. Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 2011, 44:771-778.
37. Saarela T., Risteli J., Kauppila A., Koivisto M. Type I collagen markers in cord serum of appropriate vs. small for gestational age infants born during the second half of pregnancy. Eur J Clin Invest 2001, 31:438-443.
38. Kajantie E., Hytinantti T., Koistinen R., Risteli J., Rutanen E.M., Seppälä M., et al. Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: relationships with fetal growth, gestational age, preeclampsia, and antenatal glucocorticoid treatment. Pediatr Res 2001, 49:481-489.
39. Tapanainen P., Knip M., Risteli L., Kemppainen L., Käär M.L., Risteli J. Collagen metabolites in the prediction of response to GH therapy in short children. Eur J Endocrinol 1997, 137:621-625.
40. Chandani A.K., Scariano J.K., Glew R.H., Clemens J.D., Garry P.J., Baumgartner R.N. Bone mineral density and serum levels of aminoterminal propeptides and cross-linked N-telopeptides of type I collagen in elderly men. Bone 2000, 26:513-518.
41. de Papp A.E., Bone H.G., Caulfield M.P., Kagan R., Buinewicz A., Chen E., et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 2007, 40:1222-1230.
42. Glover S.J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers on young, healthy women. Bone 2008, 42:623-630.
43. Glover S.J., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United Sates. J Bone Miner Res 2009, 24:389-397.
44. Naylor K.E., Iqbal P., Fledelius C., Fraser R.B., Eastell R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 2000, 15:129-137.
45. Hellmeyer L., Ziller V., Anderer G., Ossendorf A., Schmidt S., Hadji P. Biochemical markers of bone turnover during pregnancy: a longitudinal study. Exp Clin Endocrinol Diabetes 2006, 114:506-510.
46. Koivisto H., Hietala J., Niemelä O. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am J Gastroenterol 2007, 102:773-779.
47. Guañabens N., Parés A., Alvarez L., de Osaba MJ Martínez, Monegal A., Peris P., et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Metab 1998, 13:731-738.
48. López B., González A., Díez J. Circulating metabolism in cardiac diseases. Circulation 2010, 121:1645-1654.
49. Scheja A., Wildt M., Wollheim F.A., Åkesson A., Saxne T. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatol 2000, 39:1110-1113.
50. Kubo M., Kikuchi K., Fujimoto M., Tamaki K. Serum concentrations of carboxyterminal propeptide of type 1 procollagen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis. Arch Dermatol Res 1998, 290:253-257.
51. Jensen B.V., Johansen J.S., Skovsgaard T., Brandt J., Teisner B. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002, 98:582-589.
52. Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012, 10.1016/j.clinbiochem.2012.01.022.
53. Oikarinen A., Autio P., Vuori J., Väänänen K., Risteli L., Kiistala U., et al. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen (PICP) and aminoterminal propeptide of type III procollagen (PIIINP) in dermatological patients. Brit J Dermatol 1992, 126:172-178.
54. Autio P., Oikarinen A., Melkko J., Risteli J., Risteli L. Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol 1994, 131:660-663.
55. Vihinen M.K., Kolho K.L., Ashorn M., Verkasalo M., Raivio T. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008, 159:693-698.
56. Wisłowska M., Jakubicz D., Stepień K., Cicha M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 2009, 29:1403-1409.
57. Eastell R., Rogers A., Ni X., Krege J.H. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporosis Int 2011, 22:1927-1934.
58. Finkelstein J.S., Leder B.Z., Burnett S.M., Wyland J.J., Lee H., de la Paz A.V., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91:2882-2887.
59. Leder B.Z., Neer R.M., Wyland J.J., Lee H.W., Burnett-Bowie S.M., Finkelstein J.S. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009, 94:2915-2921.
60. Eastell R., Krege J.H., Chen P., Glass E.V., Register J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006, 22:61-66.
61. Tsujimoto M., Chen P., Miyauchi A., Sowa H., Krege J.H. PINP as an aid for monitoring patients treated with teriparatide. Bone 2011, 48:798-803.
62. Rogers A., Glover S.J., Eastell R. A randomized, double-blinded, placebo-controlled, trial to determinate the individual response in bone turnover markers to lasofoxifene therapy. Bone 2009, 45:1044-1052.
63. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
64. Vasikaran S., Cooper C., Eastell R., Griesmacher A., Morris H.A., Trenti T., et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011, 49:1271-1274.
65. Lund A.M., Hansen M., Kollerup G., Juul A., Teisner B., Skovby F. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Pediatr 1998, 87:1131-1137.
66. Kauppila S., Tekay A., Risteli L., Koivisto M., Risteli J. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur J Clin Invest 1998, 28:831-837.
67. Cundy T., Reid I.R. Paget's disease of bone. Clin Biochem 2012, 45:43-48.
68. McCloskey E., Paterson A., Kanis J., Tähtelä R., Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 2010, 46:558-565.
69. McCaig F.M., Renshaw L., Williams L., Young O., Murray J., Macaskill E.J., et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2010, 119:643-651.
70. Selander K.S., Brown D.A., Blanco Sequeiros G., Hunter M., Desmond R., Parpala T., et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007, 16:532-537.
71. Koopmans N., de Jong I.J., Breeuwsma A.J., van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007, 178:849-853.
72. Jung K., Miller K., Wirth M., Albrecht M., Lein M. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 2011, 59:604-612.